Phosphodiesterase-5 Inhibitor Treatment is Associated with Improved Survival in Pulmonary Hypertension Associated with COPD in the PVRI GoDeep Meta-Registry
Khodr Tello,Athiththan Yogeswaran,Raphael W Majeed,David G Kiely,Allan Lawrie,Evan Brittain,Jeffrey S Annis,Horst Olschewski,Gabor Kovacs,Paul M Hassoun,Aparna Balasubramanian,Ziad Konswa,Andrew J Sweatt,Roham T Zamanian,Martin R Wilkins,Luke Howard,Alexandra Arvanitaki,George Giannakoulas,Hector R Cajigas,Robert Frantz,Paul G Williams,Marlize Frauendorf,Kurt Marquardt,Tobiah Antoine,Meike Fuenderich,Manuel Richter,Friedrich Grimminger,Hossein-Ardeschir Ghofrani,Jochen Wilhelm,Werner Seeger,PVRI-GoDeep-Consortium Imad Al Ghouleh,Anastasia Anthi,John Cannon,Stephen Y Chan,Victoria Damonte,Diego Echazarreta,Christina Eichstaedt,Jean Elwing,Kai Förster,Stefano Ghio,Ekkehard Gruenig,Anne Hilgendorff,Arun Jose,Ernesto Junaeda,Stelios Orfanos,Karen Osborn,Antonella Pepe,Johanna Pepezaba,Hanni Sabbour,Sandeep Sahay,Khaled Saleh,Yuriy Sirenko,Ioan Tilea,Olena Torbas,Andrea Varga
DOI: https://doi.org/10.1016/j.chest.2024.08.016
IF: 9.6
2024-08-23
Chest
Abstract:Background: Patients with COPD frequently develop pulmonary hypertension (PH-COPD). Severe PH-COPD, identified by a pulmonary vascular resistance (PVR) >5 Wood Units (WU), is closely linked to impaired transplant-free survival. The impact of PH-targeting pharmacotherapy in this context remains unclear. Research question: Is PH-targeted therapy associated with improved transplant-free survival in PH-COPD? Study design and methods: This study included PVRI GoDeep meta-registry patients with PH-COPD and available right heart catheterization at diagnosis. We investigated PH-targeted therapy prevalence and its association with transplant-free survival using diverse statistical methods, including Cox regression and subgroup analyses based on PH severity, comorbidities, and pulmonary function tests. Immortal time bias was addressed through a landmark approach. Results: As of December 2023, the GoDeep meta-registry included 26981 patients (28% PH-Group 1, 13% PH-Group 2, 12% PH-Group 3, 10% PH-Group 4, 2% PH-Group 5, 26% undefined and 9% control). Out of these, 836 patients were diagnosed as PH-COPD and included in this analysis, with median age 66 [59,73]years, FEV1 51 [34,69]%predicted, mPAP 35 [28,44]mmHg, PVR 5 [4,8]WU, cardiac index 2.5 [2.0,2.9]L/min.m2, and mostly WHO functional class III were included. 5-year transplant-free survival was 42%, significantly worse than group 1 PH. A multivariable Cox proportional hazards model identified PVR, but not FEV1 as a major predictor of outcome. 418 patients (50%) received phosphodiesterase-5 inhibitor (PDE5i) therapy, which was associated with significantly reduced mortality: hazard ratio 0.65 [0.57,0.75] for the entire PH-COPD cohort and 0.83 [0.74,0.94] when performing landmark analysis. This PDE5i effect was robustly reproduced when performing subgroup analyses for patients with moderate/severe PH, various comorbidities, and supplemental oxygen requirement, and when assessing the impact of unobserved confounders. Interpretation: PH-COPD patients exhibit poor transplant-free survival, with PVR being a predictor of mortality. In this meta-registry, PDE5i therapy was associated with a significant reduction in mortality across all tested models.